CFO
AGIO icon

CVA Family Office’s Agios Pharmaceuticals AGIO Stock Holding History

CVA Family Office’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15
Closed -$493 – 1390
2024
Q4 		$493 Hold
15
– – ﹤0.01% 1237
2024
Q3 		$666 Hold
15
– – ﹤0.01% 1133
2024
Q2 		$647 Buy
+15
New +$541 ﹤0.01% 1137

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CVA Family Office's AGIO Position: Q1 2025 in Review

CVA Family Office sold out of Agios Pharmaceuticals (AGIO) in Q1 2025, closing a stake of 15 shares — an estimated $493 sold.

CVA Family Office first reported a position in AGIO in Q2 2024 and held it in 3 quarters. The position peaked at $666 in Q3 2024. 220 funds tracked by Wall St. Rank hold AGIO as of Q1 2025.

  • CVA Family Office reported no remaining Agios Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • CVA Family Office sold 15 Agios Pharmaceuticals shares in Q1 2025, an estimated $493.
  • CVA Family Office first reported a position in Agios Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • CVA Family Office's Agios Pharmaceuticals position peaked at $666 in Q3 2024.
  • 220 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2025.

Based on CVA Family Office's 13F filing for Q1 2025, filed 16 Apr 2025.